Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)

Vertex Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Revenue rose 7.82% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $12.2 billion (up 10.08% YoY), while the FY2025 annual figure was $12.0 billion, up 8.9% from the prior year.
• Revenue for Q1 2026 stood at $3.0 billion, down from $3.2 billion in the prior quarter.
• The five-year high for Revenue was $3.2 billion in Q4 2025, with the low at $2.1 billion in Q1 2022.
• The 5-year median for Revenue is $2.6 billion (2024), against an average of $2.6 billion.
• The sharpest annual moves came in 2022 and 2025: Revenue climbed 22.46% in 2022, then advanced 2.96% in 2025.
• Vertex Pharmaceuticals' Revenue stood at $2.3 billion in 2022, then gained by 9.34% to $2.5 billion in 2023, then advanced by 15.66% to $2.9 billion in 2024, then advanced by 9.55% to $3.2 billion in 2025, then fell by 6.37% to $3.0 billion in 2026.
• Business Quant data shows VRTX's Revenue at $3.0 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.1 billion in Q3 2025.